HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Detailed price information for Citigroup Cap XiII [C/Pn] (C-N-N) from The Globe and Mail including charting and trades.

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Eli Lilly has been making quite a bit of noise thanks to its work in diabetes and obesity. Investors turned on the company, ...

But if a company has been paying dividends for a long time, that can give investors confidence in its ability to continue ...